CASE Calls White House Drug Importation Plan Total Disaster for U.S. Consumers
September 28, 2020 In a move that can only be considered a total disaster for the safety and security...
White House Withdrawal of Rebate Program Needs Reconsideration
July 11, 2019 Back in January of this year millions cheered President Trump’s plan to finally hold pharmacy benefit managers...
The Problem With Price Caps: Why CMS Should Rethink Its Part B Proposal
This week, we submitted comments to Health and Human Services (HHS) Secretary Alex Azar, urging him to reevaluate and abandon...
CASE Submits Comments Urging Sec. Azar to Protect Medicare Part B
December 18, 2018 Dear Secretary Azar: Consumer Action for a Strong Economy (CASE)represents the interests of all American consumers by...
World AIDS Day: A Warning On Socialized Healthcare Systems
On Saturday, the world recognized World AIDS Day. Since it was first recognized as a cause of death in the...
Government Plan on Drug Pricing Ads Won’t Help Consumers
Almost everyone agrees patients should know what their medicines cost them, and that drug pricing should be made more clear...
Pharmaceutical Importation: Too Dangerous To Allow
Last week, U.S. Department of Health and Human Services Secretary Alex Azar spoke at The Heritage Foundation about the importance...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/